ClinicalTrials.gg
RecruitingNCT06732323Updated Sep 23, 2025

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

A Phase 3 interventional study of ESG401 and Investigator's Choice Chemotherapy in Triple-Negative Breast Cancer (TNBC), sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
24th of 235
504 · median 90
Started
2025
with 27 others
Phase 3
48 of 252
19 open now
Primary completion
2027-06
later than 91 of 152 live
Registered
186th of 252
by date

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 24th largest by planned enrollment of the 235 interventional ones that give a count, is one of 28 that started in 2025, is one of 48 in phase 3, reaches primary completion later than 91 of the 152 other live ones, and was the 186th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 444 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.

Read the detailed description

This is a randomized, open-label, multicenter Phase 3 study to evaluate ESG401 versus Investigator's Choice Chemotherapy (ICC) as first-line treatment in subjects with unresectable recurrent or metastatic triple-negative breast cancer.

03

Conditions studied

  • Triple-Negative Breast Cancer (TNBC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Males or females aged ≥ 18 years ;
  2. and/or cytologically confirmed TNBC;
  3. De novo or ≥ 6 months post completion of treatment with curative intent;
  4. No prior systemic anti-cancer therapy for unresectable recurrent or metastatic disease;
  5. Participants whose tumours are -negative, or Participants whose tumours are PD-L1-positive and have relapsed after prior PD-1/PD-L1 inhibitor therapy for early-stage breast cancer, or comorbidities precluding PD-1/PD-L1 inhibitor therapy;
  6. Eligible for the chemotherapy options listed as investigator's choice chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin) as assessed by the investigator;
  7. At least one per v1.1;
  8. (ECOG) performance status of 0 to 1 with no worsening within 2 weeks prior to randomization;
  9. A of at least 12 weeks;
  10. Adequate organ and bone marrow function.

Key Exclusion Criteria:

  1. Use of any anti-cancer drug within 28 days or 5 half-lives before the first investigational product administration.
  2. Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1.
  3. Prior topoisomerase I inhibitor therapy, including antibody-drug conjugate(ADC) therapy, or prior TROP2 targeted therapy.
  4. New thromboembolic events, intestinal obstruction, gastrointestinal bleeding or perforation within 6 months.
  5. Subjects with symptomatic or untreated , or those requiring ongoing treatment for CNS metastases.
  6. Patients with Primary CNS , or patients with other malignancies within 3 years prior to the first dose.
  7. Patients with uncontrollable systemic diseases.
  8. Patients with gastrointestinal diseases (such as chronic gastritis, chronic enteritis or gastric ulcers), or with a previous history of severe or chronic diarrhea.
  9. Subjects with cardiovascular disease.
  10. (HIV) infection.
  11. Active or .
  12. Known immediate or delayed reaction to irinotecan or other camptocampin derivatives such as topotecan or to have had grade≥3 gastrointestinal reactions associated with irinotecan, or allergies, or to any investigational drug or ingredient.
  13. Pregnant or lactating women.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
504 participants (estimated)

Study arms

  • Experimental
    ESG401 for injection

    IV infusion on day 1, 8 and15 of each 28 day cycle

    Drug: ESG401

  • Active comparator
    Investigator's Choice Chemotherapy

    If no prior taxane, or prior taxane in the (neo)adjuvant setting and disease-free interval (DFI) \>12 months: paclitaxel or nab-paclitaxel. Note: If subjects are intolerant or contraindicated to receive paclitaxel or albumin-paclitaxel, the investigator may choose other chemotherapy options listed in the study protocol) If prior taxane and DFI ≤ 12 months: capecitabine, eribulin. If known BRCA1/2 mutation: carboplatin

    Drug: Investigator's Choice Chemotherapy

Interventions

  • DrugESG401

    IV infusion on day 1,8, and 15 of each 28 day cycle

  • DrugInvestigator's Choice Chemotherapy

    Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)

    Defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first.

    Time frame: Randomization up to approximately 28 months

  2. Overall Survival (OS)

    Defined as the time from randomization until the date of death due to any cause.

    Time frame: Randomization up to approximately 41 months

Secondary outcomes

  1. Progression-Free Survival (PFS) assessed by Investigator

    Defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on investigator or death due to any cause, whichever occurs first.

    Time frame: Randomization up to approximately 28 months

  2. Objective Response Rate (ORR) assessed by Blinded Independent Central Review (BICR)

    Defined as the percentage of patients who achieve complete response(CR) or partial response (PR), as assessed by BICR per RECIST 1.1

    Time frame: Randomization up to approximately 28 months

  3. Disease control rate (DCR) assessed by Blinded Independent Central Review (BICR)

    Defined as the percentage of patients who achieve CR, PR or stable disease (SD), as assessed by BICR per RECIST 1.1

    Time frame: Randomization up to approximately 28 months

  4. Duration of Response (DoR) assessed by Blinded Independent Central Review (BICR)

    Defined as the time from the date of first documented CR or PR until date of documented disease progression per RECIST 1.1, as assessed by BICR or death due to any cause, whichever occurs first.

    Time frame: Randomization up to approximately 28 months

  5. Time to Response (TTR) assessed by Blinded Independent Central Review (BICR)

    Defined as the time from the date of randomization until the first documentation of CR or PR as assessed by BICR per RECIST 1.1.

    Time frame: Randomization up to approximately 28 months

  6. Objective Response Rate (ORR) assessed by Investigator

    Defined as the percentage of patients who achieve complete response(CR) or partial response (PR), as assessed by investigator per RECIST 1.1

    Time frame: Randomization up to approximately 28 months

  7. Disease control rate (DCR) assessed by Investigator

    Defined as the percentage of patients who achieve CR, PR or stable disease (SD), as assessed by investigator per RECIST 1.1

    Time frame: Randomization up to approximately 28 months

  8. Duration of Response (DoR) assessed by Investigator

    Defined as the time from the date of first documented CR or PR until date of documented disease progression per RECIST 1.1, as assessed by investigator or death due to any cause, whichever occurs first.

    Time frame: Randomization up to approximately 28 months

  9. Time to Response (TTR) assessed by Investigator

    Defined as the time from the date of randomization until the first documentation of CR or PR as assessed by investigator per RECIST 1.1.

    Time frame: Randomization up to approximately 28 months

  10. Quality of life evaluated using the NCC-BC-A scale

    To assess the impact of ESG401 on disease related symptoms and quality of life of patients using the NCC-BC-A scale

    Time frame: Randomization up to approximately 28 months

  11. Adverse events(AEs) and severe adverse events (SAEs)

    Incidence and severity of AEs and SAEs (per CTCAE 5.0), and clinically significant abnormal laboratory findings

    Time frame: From signing the ICF up to last dose plus 30 days

  12. Clearance

    Mean population clearance will be derived from pooled data of drug concentrations. Covariates of influence on drug clearance will be incorporated within a population pharmacokinetic model.

    Time frame: Randomization up to approximately 28 months

  13. Volume of distribution

    Mean population volume of distribution will be derived from pooled data of drug concentrations. Covariates of influence on volume of distribution will be incorporated within a population pharmacokinetic model.

    Time frame: Randomization up to approximately 28 months

  14. Anti-drug Antibodies

    Incidence of anti-drug antibodies.

    Time frame: Randomization up to approximately 28 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 13, 2024
StartActual
Sep 4, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2028
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06732323
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Sep 4, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 23, 2025

Study contacts

Xiaoyan Xing, PhD
Contact
xingxiaoyan@escugen.com
+86 21 5855 6098
Fei Ma, PhD
Contact
Fei Ma
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-TROP2 Antibody-drug Conjugate ESG401

Start the discussion